An Open-label Extension Study Evaluating the Safety of Zagociguat in Participants With MELAS Who Completed TIS6463-203
Latest Information Update: 14 May 2025
At a glance
- Drugs Zagociguat (Primary)
- Indications MELAS syndrome
- Focus Adverse reactions
- Acronyms PRIZM
- Sponsors Tisento Therapeutics
Most Recent Events
- 14 May 2025 New trial record